News

In this week’s episode, Managed Healthcare Executive Associate Editor Briana Contreras had the pleasure of meeting CEO of Quanterix and founder of Powering Precision Health, Kevin Hrusovsky. Quanterix is a blood-based biomarker analysis company. In this discussion, the two discussed Powering Precision Health and some tools like the Disruptive Innovation 5-step model that brings his vision closer of detecting and improving the health of patients sooner.

Matthew Bennett is senior vice president of Evernorth Care Delivery, a health services company and subsidiary of Cigna. Bennett is one of the emerging health leaders featured in the October 2021 issue of Managed Healthcare Executive. In this video he talks about the career achievement that has given him the greatest satisfaction, dissects his recent promotion and who has had the greatest influence on his life.

Matthew Bennett is one of 13 up-and-coming health leaders featured in this annual Managed Healthcare Executive series.

Ellen Beckjord, Ph.D., M.P.H., vice president of population health and clinical transformation at UPMC Health Plan in Pittsburgh, is one of the emerging health leaders featured in the October 2021 issue of Managed Healthcare Executive. In this video she talks about the career achievement that has given her the greatest satisfaction and the person who has had the greatest influence on her life.

Ellen Beckjord is one of 13 up-and-coming health leaders featured in this annual Managed Healthcare Executive series.

Before the pandemic, rural areas were ahead in telehealth adoption. That has changed during the pandemic, most obviously because many rural residents don’t have access to broadband.

The delivery of care model needs to scale across the community settings while servicing the unique needs of each patient.

In this video series, Agboola addresses two questions asked in the annual Emerging Health Leaders series: Which career accomplishment has given you the greatest satisfaction? and who has had the greatest influence on your life?

Foluso Agboola is one of 13 up-and-coming health leaders featured in this annual Managed Healthcare Executive series.

Pfizer officially seeks EUA for pediatric COVID vaccine, AstraZeneca seeks EU for COVID-19 prevention, J&J submits data for COVID-19 booster, a gene therapy is approved for leukemia, and Janssen submits Stelara for psoriatic arthritis in children.

Rinvoq, a JAK inhibitor, is still under review at the FDA as a treatment of atopic dermatitis.

Incyte will be required to conduct postmarketing study and set up patient registry to monitor whether the topical JAK inhibitor has adverse effects on mothers, fetuses and infants.

Exactly how Byooviz will be priced is unclear, noted George W. Williams, M.D., a retina specialist and past president of the American Academy of Ophthalmology. The exact cost savings will help determine whether the biosimilar gains acceptance.

Blue Plans will now have an additional home delivery option that they can choose to offer their members.

Many states only have vaguely worded qualitative standards for network adequacy for cancer care. Others have quantitative standards based on distance or waiting time.

1 in 10 patients with early-onset atrial fibrillation have gene variants associated with a cardiac disease, most commonly some form of cardiomyopathy, according to research conducted by Vanderbilt researchers. Results would justify routinizing genetic testing of young afib patients, the researchers said.

A rare mutation of the ALPK3 gene has been shown to result in more serious cases of hypertrophic cardiomyopathy.

The FDA rejected Humanigen’s application for an emergency use authorization, but the race is on to develop an effective therapy for the cytokine storms that affect patients with COVID-19.

Merck plans to seek emergency use authorization for molnupiravir as the first oral treatment for COVID-19.

The Annual report shares actual cost trends and expectations for the future of healthcare.

Health officials should consider advise that people spend more time outdoors as. way to cope with this and future pandemics, the researchers suggest.

Data show that the vaccine was 94% effective against moderate infection and 100% effective against severe disease.

Medicare negotiation of drug prices would stifle the development of much-needed therapies. Curtailing defensive medicine and rolling back excessive regulation would be a better way to control healthcare costs.

A review of more than 200 studies found no greater risk of contracting COVID-19 among those with HIV but a greater chance of experiencing a severe case.

The labeling for selective serotonin reuptake inhibitors (SSRIs) and selective serotonin-norepinephrine reuptake Inhibitors (SSNRIs) now must include information about sexual side effects in the warning and precautions and patient counseling sections.

Aetna, Cigna and UnitedHealthcare are enhancing their Medicare pharmacy benefits, including offering insulin for a copay of no more than $35 for a 30-day supply.

The FDA is scheduled make a decision on injectable cabotegravir by Jan. 24, 2022.

Approvals include a therapy for a rare disease for children and a novel migraine prevention. New regulatory applications include Biogen’s second Alzheimer’s therapy and other indications for Opdivo and Erbitux, and Pfizer submits data for COVID-19 vaccine for children.